ATE286122T1 - Protein c derivate - Google Patents

Protein c derivate

Info

Publication number
ATE286122T1
ATE286122T1 AT01904786T AT01904786T ATE286122T1 AT E286122 T1 ATE286122 T1 AT E286122T1 AT 01904786 T AT01904786 T AT 01904786T AT 01904786 T AT01904786 T AT 01904786T AT E286122 T1 ATE286122 T1 AT E286122T1
Authority
AT
Austria
Prior art keywords
derivatives
wild
protein
human protein
type
Prior art date
Application number
AT01904786T
Other languages
English (en)
Inventor
Bruce Edward Gerlitz
Bryan Edward Jones
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE286122T1 publication Critical patent/ATE286122T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01904786T 2000-02-02 2001-01-19 Protein c derivate ATE286122T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17980100P 2000-02-02 2000-02-02
US18919700P 2000-03-14 2000-03-14
PCT/US2001/000020 WO2001057193A2 (en) 2000-02-02 2001-01-19 Protein c derivatives

Publications (1)

Publication Number Publication Date
ATE286122T1 true ATE286122T1 (de) 2005-01-15

Family

ID=26875697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01904786T ATE286122T1 (de) 2000-02-02 2001-01-19 Protein c derivate

Country Status (9)

Country Link
US (1) US6841371B2 (de)
EP (1) EP1255821B1 (de)
JP (1) JP2003521919A (de)
AT (1) ATE286122T1 (de)
AU (1) AU2001232736A1 (de)
CA (1) CA2399267A1 (de)
DE (1) DE60108076T2 (de)
ES (1) ES2234807T3 (de)
WO (1) WO2001057193A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1255821B1 (de) 2000-02-02 2004-12-29 Eli Lilly And Company Protein c derivate
CA2400187A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2003073980A2 (en) * 2002-03-01 2003-09-12 T.A.C. Thrombosis And Coagulation Aktiebolag Recombinant protein c variants
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
EP1773371A4 (de) * 2004-07-23 2009-12-30 Univ Rochester Aktiviertes protein c hemmt unerwünschte effekte von plasminogenaktivator im gehirn
EP1898945B1 (de) * 2005-06-24 2012-12-19 Drugrecure ApS Atemwegs-administration eines standort-deaktivierten fviia bei entzündungskrankheiten, die den atemtrakt betreffen
CA2712057A1 (en) * 2008-01-15 2009-07-23 The University Of British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2799316B2 (ja) 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5196322A (en) 1987-12-28 1993-03-23 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
JPH0246296A (ja) 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
JP2774154B2 (ja) 1989-08-10 1998-07-09 帝人株式会社 活性化ヒトプロテインｃ誘導体
US5358932A (en) 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
ATE163048T1 (de) 1989-12-29 1998-02-15 Zymogenetics Inc Hybrides protein c
US5270178A (en) 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
ATE321846T1 (de) 1996-11-08 2006-04-15 Oklahoma Med Res Found Verwendung eines modifizierten protein-c
US5837843A (en) 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
SE9701228D0 (sv) 1997-04-03 1997-04-03 Bjoern Dahlbaeck Rekombinanta protein-C-och protein-S-varianter
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
EP1090130A1 (de) 1999-04-30 2001-04-11 Eli Lilly And Company Protein c derivaten
JP2003514545A (ja) 1999-11-19 2003-04-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
EP1255821B1 (de) 2000-02-02 2004-12-29 Eli Lilly And Company Protein c derivate
CA2400187A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
ATE298246T1 (de) 2000-03-28 2005-07-15 Lilly Co Eli Aktiviertes protein c zur behandlung von pankreatitis
WO2002070681A1 (en) 2001-03-02 2002-09-12 T.A.C. Thrombosis And Coagulation Ab Protein c variants

Also Published As

Publication number Publication date
JP2003521919A (ja) 2003-07-22
US20030207435A1 (en) 2003-11-06
WO2001057193A2 (en) 2001-08-09
EP1255821B1 (de) 2004-12-29
CA2399267A1 (en) 2001-08-09
ES2234807T3 (es) 2005-07-01
WO2001057193A3 (en) 2002-02-07
DE60108076D1 (de) 2005-02-03
AU2001232736A1 (en) 2001-08-14
DE60108076T2 (de) 2006-03-16
US6841371B2 (en) 2005-01-11
EP1255821A2 (de) 2002-11-13

Similar Documents

Publication Publication Date Title
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
EP1465854A4 (de) Chalconderivate und deren verwendung zur behandlung von krankheiten
DE60034155D1 (de) Adamantanderivate zur Behandlung von entzündlichen, immunologischen und kardiovaskulären Erkrankungen
DE69635671D1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
DE69831566T2 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
MXPA05013641A (es) Trampas de vegf y usos terapeuticos de las mismas.
EP1429793A4 (de) Nucleinsäure und entsprechendes protein, steap-1, bei der behandlung und zum nachweis von krebs
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
PT1196444E (pt) Conjugados de exendina-4 e seus usos medicos
SE9800836D0 (sv) New Compounds
DE60143292D1 (de) Varianten des menschlichen Koagulationsfaktors VII
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
DE60143065D1 (de) Bildgebende Verfahren, Diagnose und Behandlung von Krankheiten
DE60131569D1 (de) Genetisch veränderter herpes virus für die behandlung von herz- und gefässerkrankungen
ATE286122T1 (de) Protein c derivate
ATE353366T1 (de) Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
EP1544214A4 (de) NICHT-NEUTRALISIERENDE ANTI-aPC-ANTIKÖRPER
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE60044453D1 (de) Gentherapie für zerebrale gefässerkrankungen
WO2001036462A3 (en) Protein c derivatives
BR0006088A (pt) Derivados de proteìna c
ATE291586T1 (de) Humanes antibiotisches protein
EP1409710A4 (de) Nukleinsäure und dieser entsprechendes, 161p5c5 genanntes, für die behandlung und den nachweis von krebs geeignetes protein
ATE302008T1 (de) Behandlung von entzündlichen erkrankungen
Xue et al. Activated protein C stimulates expression of angiogenic factors in human skin cells, angiogenesis in the chick embryo and cutaneous wound healing in rodents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties